Ashland earnings date
Want to see ASH full AI Analyst Report?
Ashland (ASH) Q4 2026 Earnings Report
ASH Q4 2026 EPS Results
- Actual EPS
- $1.12
- Consensus EPS
- $1.28
- Beat/Miss
- Missed by -$0.15
- One Year Ago EPS
- $1.08
ASH Q4 2026 Revenue Results
- Actual Revenue
- $498.00M
- Expected Revenue
- $501.76M
- Beat/Miss
- Missed by -$3.76M
- YoY Revenue Growth
- +4.18%
Earnings Announcement Details
- Quarter
- Q4 2026
- Date
- 11/03/2026
- Time
- After Close
- Conference Call
- Tuesday, November 3, 2026
Ashland's next earnings date is estimated for February 2, 2027, based on past reporting schedules.
Q4 2026 Earnings Call Audio
Q4 2026 Earnings Slide Deck
Q4 2026 Earnings Call Summary
The call was predominantly positive. Ashland reported broad-based sales and volume growth, strong performance in Life Sciences and Personal Care, improving Intermediates profitability, substantial cash generation, strategic initiative outperformance, and a constructive fiscal 2027 outlook. These strengths were partially offset by Specialty Additives profitability pressure from Hopewell, soft construction and energy and resources markets, foreign-currency headwinds, higher planned capital expenditures, and lower expected free cash flow conversion.
For fiscal 2027, Ashland expects sales of $1.905 billion-$1.975 billion, adjusted EBITDA of $405 million-$435 million, ongoing free cash flow conversion greater than 40% of adjusted EBITDA, capital expenditures of up to approximately $140 million, and approximately $10 million of net productivity and manufacturing optimization benefits; globalize and innovate are targeted to contribute approximately $20 million and $45 million of incremental sales, respectively, representing a 25% increase in the combined incremental sales versus 2026, while foreign currency is expected to create headwinds of approximately $20 million-$25 million in sales and $7 million-$10 million in Adjusted EBITDA. Demand in Life Sciences and Personal Care is expected to remain resilient, Coatings and Performance Specialties are expected to build on recent commercial momentum, Hopewell output is expected to increase by about 25% roughly in fiscal 2027 with another order of magnitude similar in the following year, and over time free cash flow is expected to be greater than 50% relative to adjusted EBITDA.
- Fourth-Quarter Sales and Volume GrowthFourth-quarter sales increased 4% to $498 million, with volumes up 3% and pricing up 2%. Pricing covered cost inflation across all business units, while higher volumes, favorable mix, and pricing supported adjusted EBITDA growth.
- Adjusted EBITDA and Earnings ImprovementFourth-quarter adjusted EBITDA increased 2% to $121 million. Adjusted operating income rose to $77 million from $71 million, while adjusted income from continuing operations increased to $52 million, or $1.12 per diluted share, from $50 million, or $1.08 per diluted share.
- Strong Cash Generation and Financial FlexibilityCash flow from operating activities increased to $90 million from $40 million, primarily due to lower working capital. Ongoing free cash flow increased to $74 million from $52 million, with conversion of 61% of adjusted EBITDA versus 44% in the prior-year quarter. Ashland ended fiscal 2026 with $480 million of cash, $976 million of total liquidity, and net leverage of 2.3x.
- Life Sciences Growth and Record MarginLife Sciences sales increased 4% to $180 million, led by broad Pharma growth. Pharma sales increased approximately 6%, marking the sixth consecutive quarter of year-over-year volume growth. Adjusted EBITDA increased 16% to $64 million, and adjusted EBITDA margin expanded 380 basis points to an all-time high of 35.6%.
- Pharma Commercial Momentum and InnovationPharma growth was broad-based across major regions and technology platforms, including VP&D, Cellulosics, injectables, and film coatings. Ashland launched Permexa, a sodium caprate permeation enhancer for oral biologics, with more than 60 active customer engagements underway. The company also reported increasing adoption of recently launched high-value offerings.
- Personal Care Growth and Margin ExpansionPersonal Care sales increased 8% to $163 million, representing the third consecutive quarter of mid-single-digit growth. Adjusted EBITDA increased 14% to $49 million, and adjusted EBITDA margin expanded 160 basis points to 30.1%. Growth was predominantly volume-driven, with approximately 7% of the 8% growth coming from volume.
- Personal Care Globalized Businesses and InnovationBiofunctional Actives and Microbial Protection each delivered double-digit growth, while Care Ingredients increased approximately 7%, led by double-digit hair-care growth and high single-digit skin-care growth. Ashland launched easy-hance, a super-wetting agent designed for curly hair. The company said its high-margin biofunctional actives and microbial protection businesses are expected to continue growing at double-digit rates in 2027 and beyond.
- Specialty Additives Commercial PerformanceWithin Specialty Additives, Coatings sales increased by a high single-digit percentage and Performance Specialties delivered double-digit growth with continued share gains across regions. China delivered its third consecutive quarter of year-over-year sales growth. Pricing increased approximately 5% and covered raw material cost inflation.
- Intermediates Margin ImprovementIntermediates sales were $33 million, in line with the prior-year quarter, while merchant sales increased 4% on favorable mix and continued strength in NMP. Adjusted EBITDA increased to $6 million from $5 million, and adjusted EBITDA margin expanded 300 basis points to 18.2%, supported by favorable merchant mix, disciplined pricing, and strong cost performance.
- Execute Strategy BenefitsVP&D optimization and small-plant consolidation delivered approximately $18 million of fiscal 2026 benefits, including $15 million from VP&D and $3 million from small-plant consolidation. Ashland said these initiatives reduced the structural cost base and strengthened its operating foundations.
- Globalize and Innovate OutperformanceGlobalize and innovate generated approximately $52 million of incremental fiscal 2026 sales, nearly 50% above the combined target of $35 million. Globalize generated approximately $26 million versus a $20 million target, while innovate generated approximately $26 million versus a $15 million target.
- Fiscal 2027 Growth TargetsFor fiscal 2027, Ashland is targeting approximately $20 million of incremental globalized sales and $45 million of incremental innovate sales, representing a 25% increase in combined incremental sales versus 2026. The company is also targeting approximately $10 million of net productivity and manufacturing optimization benefits.
- Innovation Pipeline ExpansionAcross seven scalable technology platforms, Ashland has filed over 50 patents and launched 23 products, including 12 launches since May 2025. Several platforms have moved beyond validation into commercial launch and broader customer adoption.
- New Energy Storage Customer WinAshland secured a significant, multi-year U.S. contract with a large battery, electric-vehicle, and energy-storage customer. The company said the contract should provide meaningful volume and loading stability for the Intermediates business and integrated footprint, with customer volumes ramping over the next 6-12 months.
- Fiscal 2027 Revenue and EBITDA OutlookAshland expects fiscal 2027 sales of $1.905 billion-$1.975 billion and adjusted EBITDA of $405 million-$435 million. The outlook assumes continued commercial momentum, improving operating performance, disciplined pricing, and resilient demand in Life Sciences and Personal Care.
- Pricing Discipline and Cost RecoveryPricing increased 2% in the fourth quarter after being down 2 points in the second quarter, a 400-basis-point swing over the last couple of quarters. Management said pricing actions covered inflation across the business units and expects carryover pricing to be a modest tailwind in the first half of fiscal 2027.
- Recovery from Calvert City OutageAshland said it recovered from the Calvert City outage, with adjusted EBITDA margin increasing roughly 400 basis points from the second quarter to the fourth quarter. The company said production has normalized and the related prior-year impacts have been lapped.
- Long-Term Capital Allocation FlexibilityManagement said bolt-on acquisitions in Pharma and Personal Care remain priorities, along with assets supporting new technologies and geographic growth. The company also highlighted $480 million-plus of cash and an undrawn revolver as flexibility ahead of the January 2028 EUR 500 million bond maturity.
ASH Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 02, 2027 | 2027 (Q1) | 0.38- | 0.26 | ― | ― |
| Nov 03, 2026 | 2026 (Q4) | 1.271.12 | 1.08 | 3.70% (+0.04) | |
| Jul 28, 2026 | 2026 (Q3) | 0.981.02 | 1.04 | -1.92% (-0.02) | |
| Apr 28, 2026 | 2026 (Q2) | 0.960.91 | 0.99 | -8.08% (-0.08) | |
| Feb 02, 2026 | 2026 (Q1) | 0.260.26 | 0.28 | -7.14% (-0.02) | |
| Nov 04, 2025 | 2025 (Q4) | 1.241.08 | 1.26 | -14.29% (-0.18) | |
| Jul 29, 2025 | 2025 (Q3) | 1.211.04 | 1.49 | -30.20% (-0.45) | |
| Apr 30, 2025 | 2025 (Q2) | 1.100.99 | 1.27 | -22.05% (-0.28) | |
| Jan 28, 2025 | 2025 (Q1) | 0.170.28 | 0.45 | -37.78% (-0.17) | |
| Nov 06, 2024 | 2024 (Q4) | 1.281.26 | 0.41 | 207.32% (+0.85) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


